Introduction
The D 1 receptor is the main mediator of dopamine (DA) effects in the prefrontal cortex (PFC). The majority of DA receptors in the PFC are of the D 1 subtype, 1, 2 and display bilaminar distribution (high in layers I, II, IIIa, V and VI; low in IIIb and IV). 3, 4 Pharmacological, electrophysiological and anatomical evidence suggest that D 1 receptors are critical mediators of the direct and indirect modulatory effect of DA on the activity of pyramidal cells. [5] [6] [7] [8] We have previously reported increased availability of the D 1 receptor measured with [ 11 C]NNC 112 and positron-emission tomography (PET) in the dorsolateral PFC (DLPFC) of patients with schizophrenia compared with healthy volunteers. The increased [ 11 C]NNC 112 binding was predictive of poor performance on a working memory task. 9 A possible explanation for this observed increase in D 1 availability may be chronic hypostimulation of the D 1 receptor, with a compensatory but inefficient upregulation, in response to a chronic deficit of cortical DA transmission underlying the cognitive impairment in schizophrenia.
The fact that low DA tone is associated with upregulation of the in vivo binding of [ 11 C]NNC 112 to D 1 receptors has been well documented in rodents. 10 A similar relationship has been demonstrated in non-human primates. Chronic administration of N-methyl-D-aspartate receptor antagonists is known to decrease prefrontal DA. 11 In monkeys chronically treated with the N-methyl-D-aspartate receptor antagonist MK801, levels of prefrontal DA measured by microdialysis were found to be decreased, and D 1 receptor availability, as measured with positron-emission tomography (PET) and [ 11 C]NNC 112, was increased. 12 A similar increase in prefrontal [ 11 C]NNC 112 binding was reported in human chronic ketamine users. 13 Together, these data demonstrate that sustained lower levels of prefrontal DA are associated with increased [ 11 C]NNC 112 binding. The action of DA released in the synaptic cleft is terminated either by DA transporter (DAT) reuptake, diffusion out of the synapse, or catabolism by catechol-O-methyltransferase (COMT). Levels of DAT are high in the striatum, where transporters are present at the synaptic cleft, and low in the cortex, where their localization is more distant from the site of release in both rodents 14 and monkeys. 15 Reuptake presumably dominates removal of DA in the striatum, while COMT is likely to have a larger role in the regulation of DA transmission in cortex. The human COMT gene contains a common functional polymorphism, a valine-to-methionine substitution at codon 158 (val158met). The Met allele is associated with relatively lower enzymatic activity, whereas the Val allele is associated with higher activity, 16 including in the human brain. 17 In healthy subjects, the presence of the valine allele is associated with lower performance and altered DLPFC activation during completion of cognitive tasks related to prefrontal cortex function, such as the Wisconsin Cart Sort Task 18 and the N back task. 19 Deletion of the COMT gene in mice results in higher DA levels in the frontal cortex, whereas levels of DA in the striatum and hypothalamus are unaffected, presumably due to the influence of DAT in these subcortical regions. 20 Although there is considerable preclinical evidence in support of an association between the Val allele of the COMT gene and low prefrontal DA, such a relationship has not yet been directly documented in the living human brain. In this study, we took advantage of the ability of [ 11 C]NNC 112 PET imaging to provide information about sustained DA tone to study the effect of COMT genotype on prefrontal DA tone in humans. We hypothesized that homozygotes for the Val allele will show higher [
11 C]NNC 112 cortical binding compared with heterozygotes or homozygotes for the Met allele, whereas striatal differences would be smaller between the groups, due to the more limited role of COMT in regulating DA in the striatum.
Materials and methods

Subjects
Twenty-eight healthy volunteers who underwent PET [ 11 C]NNC 112 scans as controls for various imaging studies from the Division of Functional Brain Mapping at New York State Psychiatric Institute, participated in this study. The study was approved by the Institutional Review Board of the New York State Psychiatric Institute. All subjects provided written informed consent. In each case, at the time of the PET scan, the absence of pregnancy, medical, neurological or psychiatric history assessed with a structured clinical interview DSM-IV (SCID-NP) (including alcohol and drug abuse or current use of psychotropic medications) was assessed by history; review of systems; physical examination and routine blood tests, including pregnancy test, urine toxicology and electrocardiogram. The data presented here represent all healthy subjects who fulfilled the criteria described above, and for whom we were successful in obtaining both [ Genetic testing DNA was extracted from whole blood of subjects using the PUREGENE DNA purification kit (Gentra Systems, Minneapolis, MN, USA). For each subject, a fragment including codon 158 of the COMT gene was amplified from a total of 10-15 ng of genomic DNA. The G/A polymorphism (rs4680) located in the amplified fragment was detected by Taqman 5 0 nuclease extension assay. The TaqMan Drug Metabolism Genotyping pre-made assay no. rs4680C__25746809_50 (Applied Biosystems, Foster City, CA, USA) was used to amplify the fragment and detect single-nucleotide polymorphism. Assays were performed either at the Brain Disorders Branch of the National Institute of Mental Health's laboratory or later at the New York State Psychiatric Institute. 
Radiochemistry
Input-function measurement
Following radiotracer injection, arterial samples were collected every 10 s with an automated sampling system for the first 2 min, and manually thereafter at longer intervals. A total of 30 samples were obtained per scan. Following centrifugation (10 min at 1800 g), plasma was collected in 200-ml aliquots and activities were counted in a gamma counter (Wallac 1480 Wizard 3M Automatic Gamma Counter).
Six samples (collected at 2, 8, 16, 30, 50 and 70 min) were further processed by high-pressure liquid chromatography to measure the fraction of plasma activity representing unmetabolized parent compound, as described previously. 22 The measured unmetabolized fraction of [ 11 C]NNC 112 in arterial plasma was fitted to a bi-exponential function, which was then multiplied with the (decay corrected) measured plasma activity to generate a sampled arterial plasma input function. The sampled input function was then fitted (from the time of peak activity) to a sum of three exponential functions. The plasma-free fraction (fp) was also measured. Plasma clearance of unmetabolized [ 
Image analysis
Positron-emission tomography emission data were attenuation-corrected using transmission scans and frames were reconstructed by filtered backprojection using a Shepp filter (cut-off 0.5 cycles/projection ray).
A T1-weighted magnetic resonance image (MRI) was acquired for each subject ( Figure 1 ) and PET data were registered to the MRI using the AIR algorithm 23 in the MEDx software environment (Medical Numerics, Sterling, VA, USA). Regions of interest (ROIs) were drawn on each subject's MRI and then transferred to the coregistered PET data. Time-activity curves were formed for each ROI by measuring the mean activity in the ROI in each frame. The striatal subregions included were dorsal caudate (DCA), dorsal putamen (DPU) and ventral striatum (VST). The cortical regions included were DLPFC, medial PFC (MPFC), orbito-frontal cortex (OFC), anterior cingulate (ACIN), temporal cortex (TEM), parietal cortex (PAR) and occipital cortex (OCC). The limbic regions included were amygdala (AMY) and hippocampus (HIP). Striatal subregions were defined as in Mawlawi et al. 24 All other regions were drawn as defined in Abi-Dargham et al. 22 A gray/white tissue segmentation procedure 25 was applied to cortical regions so that only gray matter was included in the cortical ROIs. The cerebellum was included as a reference region.
Receptor-parameter estimation
Outcome measures that were examined in the study were BP P , equal to f p B max /K D , and BP ND , equal to f ND B max /K D . Here, f p is the fraction of unmetabolized radioligand in arterial plasma that is not bound to protein and f ND is the free fraction of free plus nonspecifically bound radioligand in brain tissue. 26 B max (nM) is the regional density of receptors available for binding to radioligand and K D (nM) is the reciprocal of the affinity of radioligand for receptors. Both outcome measures were measured indirectly as the differences and ratios of regional distribution volumes. Total distribution volume (V T ) in a region was defined as the equilibrium ratio of the total concentration of radioligand in that region to the arterial plasma concentration, and is equal to the sum of the free plus nonspecifically bound distribution volume (V ND ) and BP P . V T was estimated by non-linear least-square minimization and kinetic modeling with a two-tissue compartment model (2TCM) in the ROIs and a one-tissue compartment model (1TCM) in the cerebellum, as described previously. 22 Fits were performed with programs developed in-house in the Matlab programming environment (Mathworks, Natick, MA, USA). Due to negligible concentration of D 1 receptors in the cerebellum, 27 V T in that region was taken as an estimate of V ND , which was assumed to be equal across all brain regions. Outcome measures were then estimated as BP P ¼V T ðROIÞ À V T ðcerÞ
Statistics
Outcome-measure data (BP ND and BP P ) were tested for regional effects of COMT genotype using a linear mixed-effect model, with subjects as the random effect and genotype as the fixed effect. This approach accounts for within-subject, between-region correlation by modeling within-subject covariance, allowing an overall test of effect of genotype without the need for multiple comparison tests that would result from treating regions as independent measurements. Subjects who were homozygous for the valine allele (Val/ Val) were compared with all others, met homozygotes (met/met) and Met/Val heterozygotes who were pooled into one group. Subgroup analysis was performed with cortical and limbic regions in one subgroup and striatal subregions in another, to test if the effect of allele differed between regions with high versus low DAT. Analyses were performed with and without age as a covariate. Analyses were performed in the SAS software environment (v. 9.1, SAS Institute Inc., Cary, NC, USA). Other parameters (demographics, scan parameters) were tested with two-group t-tests.
Results
Demographic data are provided in Table 1 . Of the 28 healthy volunteers, 11 were Val/Val, 3 met/met and 14 were Met/Val. Age was not significantly different between genotypes, but approached trend level (P = 0.16; Table 1 ). The two groups (Val/Val and Met carriers) contained similar ethnic representations. Scan parameters are provided in Table 2 . There were no significant differences between genotypes in f p , clearance, specific activity, injected activity, injected mass or V ND (cerebellar V T ). Regional means for BP ND and BP P are displayed by genotype in Table 3 . Subgroup analysis showed cortico-limbic BP ND to be significantly higher for the Val/Val group than for Met carriers (P = 0.029), whereas no between-group differences were detectable in the striatal subregions (P = 0.779). Results for BP ND were similar when covarying for age (cortico-limbic: genotype, P = 0.033, age, P = 0.784; striatum: genotype, P = 0.756, age = 0.874). Subgroup analysis showed BP P to be higher at the trend level in the Val/Val group compared with others (P = 0.139), with no detectable difference in striatal subregions (P = 0.722). Covarying for age had the effect of increasing the significance of genotype for BP P in cortico-limbic regions but not striatum (corticolimbic: genotype, P = 0.106, age, P = 0.460; striatum: genotype, P = 0.888, age, P = 0.510). genotype Val/Val compared with those with either Met/Val or Met/Met COMT genotype, whereas such differences were not observed in the striatal regions. These results have two implications: first, that COMT genotype has a differential effect in cortico-limbic versus striatal regions as predicted from the differential distribution of the DAT in these regions, 14 consistent with results from knockout mice 28 and from studies with COMT inhibitors. 29 The second implication is that the upregulation detected here is yet another example of an observed increase in D 1 receptors in a condition of low DA tone due, in this case, to the higher efficiency of the COMT Val/Val enzyme in clearing DA in those brain regions. This further supports the concept initially described with the finding of elevations in the schizophrenia study, and is consistent with the interpretation that the increase indicates a deficit in cortical DA transmission in patients with schizophrenia. 9 This study is partially retrospective, as some subjects were called back after their PET scans to participate in the genetic arm. However, this should not impact the data, as they all fulfilled similar criteria for absence of any disease state, medical or psychiatric, as well as absence of substances use or dependence at the time of the scan and at the time of the genetic study. These exclusions were important to prevent the influence of factors that may have affected D 1 binding independent of genotype.
Some methodological issues should be considered in evaluating these results. Data acquisition was blind to genotype, as we obtained the genetic data from all subjects who agreed to provide it at the time of the scan or later, without a priori screening for matching parameters between groups. One strength worth noting is that groups were well matched for all relevant parameters, ethnicity, scan parameters, nonspecific binding in plasma and brain, except for a trend level difference in age. For this last reason, we performed additional analyses including age as a covariate. When included in the linear model, age was not significant and caused negligible changes in all other statistical outcomes; both analyses, with and without age as covariate, support the hypothesis of higher receptor availability in the cortex of Val/Val subjects compared with others. Further, the observation that there was no significant difference between groups in striatal subregions serves as an internal control to show that there was not a global difference in specific binding between groups (as might be expected from age-related differences) but rather, differences only in brain regions where COMT activity is more predominant than DAT in regulating DA (Figure 2 ). There were no significant differences in the plasma-free fraction (f p ) or equilibrium nonspecific binding (V ND ) between groups, implying no significant difference between groups in brain-free fraction (f ND ) either (Table 2 ). This in turn supports the validity of both receptor-related outcome measures, BP ND and BP P . The difference by genotype did not reach the same level of significance for BP P as it did for BP ND . This may be due to the additional source of variance (arterial plasma data) in BP P that is essentially normalized away in BP ND .
A total of 39% of the sample was found to be homozygotic for the Val allele, 11% were homozygotic for the Met allele and 50% of subjects were heterozygotes. This is consistent with the distribution of these alleles reported for a global population in the NCBI SNP database (refSNP ID: rs4680).
The increase was observed to be generalized across many regions of the brain, including various cortical regions as well as amygdala and hippocampus, suggesting that this functional polymorphism (val158met) in the COMT gene may affect the function of many regions, beyond the DLPFC, the region that was initially most studied. Studies had shown that the polymorphism accounts for some of the individual variability in executive function mediated by the DLPFC; 18 more recently it was also shown to affect the function of the cingulate during a specific attentional task 30 and hippocampus during declarative memory processing. 31 It is also consistent with the role of COMT in processing of affective arousal and information 32 which may involve limbic and cortical circuitry and is consistent with its high levels in cortical and limbic regions in the brain. 33, 34 We would predict from the data presented here that this polymorphism may also account for variability in function in tasks depending on the orbito-frontal cortex and other cortical regions.
One weakness of the study is the recently discovered and described lack of selectivity of [ 11 20 and administration of tolcapone, a selective COMT inhibitor, did not affect 5-HT overflow in microdialysis studies in rats. 29 However, a direct measurement with a specific tracer for D 1 or 5-HT 2A receptors would be needed to confirm this assumption.
This finding, along with the findings in DAdepleted rats, 10 in the DLPFC of chronically MK801-treated monkeys, 12 and in chronic ketamine users, 13 represents one of the converging lines of evidence for upregulation of D 1 receptors in conditions of low DA, as created either by DA depletion or N-methyl-Daspartate blockade, and supports the concept that a similar cortical DA deficit may exist in schizophrenia, although it does not represent direct evidence for it. Studies assessing DA directly in the cortex are needed for such evidence, but have unfortunately been impossible for technical reasons. Nevertheless, these data, together, suggest that D 1 receptors measured with [ 11 C]NNC 112 can be considered a biomarker for low DA tone. A biomarker could be used to classify patients into subgroups and target specific therapeutic interventions involving D 1 stimulation to these specific subgroups.
Finally, the high-activity Val allele was found to be slightly increased in patients with schizophrenia compared with controls in some studies, 18, 20, [36] [37] [38] but not in all. [39] [40] [41] It has been suggested that the influence of this allele on schizophrenia susceptibility may vary for different ethnic populations 42 and that other variants in COMT modulate the effect of Val/Met on prefrontal function. 43 However, this study clearly implicates that the COMT Val/Val allele may further compromise prefrontal DA function in individuals with schizophrenia.
Conclusion
In conclusion, our results represent further evidence that COMT plays an important role in modulating DA levels in cortical and limbic regions of the brain, and show, for the first time in the human brain, that the val158met polymorphism is a genetic factor accounting for variability across individuals in D 1 receptor availability. As D 1 is a critical mediator of DA transmission in these brain regions, these findings contribute to the understanding of one of the steps involved in the cascade of events linking genes to the cellular components underlying function
